Reading Time: 3 minutesIntroduction Phosphodiesterase type 5 inhibitors (PDE5i), such as sildenafil citrate (Viagra), have revolutionized erectile dysfunction (ED) treatment since their approval by the U.S. Food and Drug Administration (FDA) in 1998. Widely prescribed to American males, particularly those aged 40-70, Viagra enhances cyclic guanosine monophosphate (cGMP) levels, promoting vasodilation in penile tissues. However, post-marketing surveillance has identified rare but serious adverse events, including sudden sensorineural hearing loss (SSNHL) and tinnitus. This retrospective audiological study examines the incidence, risk factors, and audiometric profiles of hearing impairment in a cohort of 12,456 U.S. males using sildenafil, drawing from electronic health records (EHRs) linked … Continue reading →